Hofseth BioCare ASA: Disclosures of Large Shareholdings

Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the " Company ") on 27 October 2025 regarding completion of a private placement (the " Private Placement ") of new shares in the Company. The following shareholders of the Company have, on 27 October 2025, been allocated new shares in the Private Placement which implies that their holdings have surpassed a notifiable threshold: Guy Urquhart have subscribed for 55,444,444 new shares in the Private...

Ålesund, 27/10/2025 (informazione.news - comunicati stampa - cibi e bevande)

Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the " ") on 27 October 2025 regarding completion of a private placement (the " ") of new shares in the Company.

The following shareholders of the Company have, on 27 October 2025, been allocated new shares in the Private Placement which implies that their holdings have surpassed a notifiable threshold:

The following shareholders have had their holdings diluted as a consequence of the Private Placement and thereby surpassed a notifiable threshold:

This disclosure is made pursuant to section 4-2 of the Norwegian Securities Trading Act and is subject to the disclosure requirement pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jon Olav Ødegård, CEO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no